RE:RE:RE:RE:Buddy of mine responded to me on a previous post hereNice little hammer today...maybe we close green for the weekend tomorrow ahead of another attempt to crack resistance next week
barcodewhiz wrote:
No problem...
There is no sugarcoating that this waiting is really tough....its all SO magnfied because of our shite experience for the last 10 months. But you only need to look at the title of the Panmure Gordon update from today to see how normal it is when it comes to dealing with regulators on major issues / approvals. "SHOW ME A DRUG DEVELOPER THAT DOESNT EXPERIENCE DELAYS, I'LL SHOW YOU A COMPANY THAT DOES NOTHING "
The problem with these delays specifically.... is that they are on the back of so many various delays we have experienced over the years from this management team's overoptimism.... so it just exacerbates the overt fear.... probably unnecessarilly in this case.
Look at a guy like RBC Analyst Doug Miehm.... the guy is so gun shy he is afraid of his own shadow when it comes to Prometic. He is completely unwilling to stick his neck out at all at this point... and instead he just coveres his asz by outlining / highliting every risk... even if the actuall probability is negligible.
Sanjay Jha's update has balls... he is willing to outline the Fibrogen / Galapagos valuation inequity as an opportunity.... just like CC Abbott did on Seeking Alpha....and i fully concur with that logic
Everything I am hearing from Mgmt is suggesting that the FDA process is very close to a positive conclusion..... I remain hopeful that we will get the PDUFA date any day now.... and things will start rolling..... like Sanjay said so eloquently....
" The commercial Launch of Ryplazim is now expected in Q1/18 and not Q4/17 as previously anticipated. For a therapeutic that has market potenial of $8B, a three month delay is insignificant"
and I will add this prediction.... in 60 days or less .... we will not see another post at all from the existing pack of shorts